Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 17, 2022

SELL
$2.27 - $5.1 $185,797 - $417,429
-81,849 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.21 - $7.61 $344,584 - $622,870
81,849 New
81,849 $391,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $186M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Sender CO & Partners, Inc. Portfolio

Follow Sender CO & Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sender CO & Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sender CO & Partners, Inc. with notifications on news.